ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Announces $10.0 Billion Senior Notes Offering to Fund Apogee Acquisition
AbbVie Inc. has entered into an underwriting agreement to issue and sell nine series of senior notes with an aggregate principal amount of $10.0 billion. The...
AbbVie Beats on Revenue, Then Cuts Its Own Profit Forecast — Can a $10.9 Billion Bet on Eczema Justify Six Years of Thinner Earnings?
Shares slid 3.8% to $247.52 this morning after AbbVie delivered a strong Q2 beat but simultaneously trimmed its full-year profit outlook to absorb the cost of...
🔴 AbbVie is trading 3.8% down today after trimming profit outlook despite strong Q2 results
AbbVie is trading 3.8% down at $247.52 after trimming its 2026 profit outlook to fund a $10.9 billion acquisition of Apogee and accelerate pipeline...
AbbVie's second quarter revenue grew 10.2% to $16.99B, beating estimates on strong immunology franchise performance.
AbbVie reported second quarter net revenues of $16.99 billion, an increase of 10.2% year-over-year, while adjusted diluted EPS was $3.65, a 22.9% increase from...
🔴 AbbVie is trading 3.1% down today as investors position ahead of Q2 earnings
AbbVie is trading 3.1% down at $255.21 as investors position ahead of its Q2 2026 earnings report scheduled for July 31, 2026. • The price action suggests...
AbbVie Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 31, 2026
AbbVie's Q2 2026 consensus revenue is $16.81 billion and EPS is $3.66, with shares recently trading at $265.52 against an average analyst target of...
AbbVie secures EU approval for Rinvoq, first systemic treatment for vitiligo
The European Commission approved AbbVie’s Rinvoq (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 and older. This decision...
AbbVie’s RINVOQ Wins EU Approval, First JAK Inhibitor for Hair Loss
The European Commission approved AbbVie’s RINVOQ (upadacitinib) to treat severe alopecia areata in adults and adolescents aged 12 and older. This decision...
🟢 AbbVie is trading 3.1% up today on pre-earnings positioning and immunology pipeline optimism
AbbVie is trading 3.1% up at $264.85 as investors position ahead of its July 31, 2026, Q2 earnings release. • Recent analyst price-target increases and...
AbbVie and Genmab Miss Survival Goal in Phase 3 Lymphoma Trial
AbbVie and development partner Genmab announced that epcoritamab failed its primary goal in the Phase 3 EPCORE DLBCL-1 trial. The study evaluated the drug in...
AbbVie wins EU approval for Boey, a rapid-onset frown line treatment
AbbVie’s Allergan Aesthetics received European Commission approval for Boey (trenibotulinumtoxinE). The authorization covers all 30 European Economic Area...
🟢 AbbVie is trading 3.15% up today on broad healthcare sector strength
AbbVie is trading at $251.79 (+3.15%) in mid-morning trading, driven by broad strength across the healthcare sector. • The Health Care Select Sector SPDR Fund...
AbbVie lowers second quarter and full-year 2026 EPS guidance by $0.17 due to a $291 million R&D expense.
AbbVie updated its financial guidance for the second quarter and full-year 2026, lowering its adjusted EPS forecast to incorporate a significant research and...
AbbVie Faces US National Security Probe Over China Clinical Trials
A bipartisan U.S. House committee has launched a national security investigation into AbbVie's clinical drug trials in China. The probe, led by the House...
AbbVie stock jumps 4.2% on positive EU regulatory opinions for RINVOQ
AbbVie received two positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for RINVOQ (upadacitinib). The...
AbbVie Hits Phase 3 Goal, Cutting Lymphoma Progression Risk by 60%
AbbVie announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial for epcoritamab on June 29, 2026. The study evaluated epcoritamab in...
AbbVie shares jump 17%, driven by pediatric approvals and Apogee deal
AbbVie reported a 17% increase in its stock price during June 2026. The company secured expanded European Union approval for MAVIRET to treat acute and...
🟢 ABBV is trading 3.4% up today on $10.9 billion all-cash Apogee acquisition
ABBV is trading 3.4% higher at $251.38 following the announcement of a $10.9 billion all-cash acquisition of Apogee Therapeutics to expand its immunology...
🟢 ABBV is trading 3.1% up today following $10.9 billion acquisition of Apogee Therapeutics
• AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction. • The deal is expected to expand AbbVie's...
🟢 ABBV surges 6.1% in pre-market on continued momentum from $10.9 billion Apogee Therapeutics acquisition
ABBV is trading at $229.70, up 6.1% in pre-market, extending gains following its strategic acquisition of Apogee Therapeutics. • The pharmaceutical giant...